Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of CHIR-258 (TKI258) in Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2011
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable